

40045545-11402-001

**TITLE:           METHODS OF MODIFYING CELL STRUCTURE  
                  AND REMODELING TISSUE**

**INVENTOR:       MAHIN D. MAINES**

**DOCKET NO:    176/60981 (UR 6-11402-1001)**

## METHODS OF MODIFYING CELL STRUCTURE AND REMODELING TISSUE

This application claims the benefit of U.S. Provisional Patent  
5 Application Serial No. 60/261,500, filed January 12, 2001, which is hereby  
incorporated by reference in its entirety.

This work was supported by the U.S. National Institutes of Health  
under Grant Nos. ES04066 and ES04391. The U.S. Government may have certain  
rights in the invention.

10

### FIELD OF THE INVENTION

The present invention relates to methods of modifying cell structure  
and remodeling tissue which involve modulating the intracellular levels of biliverdin  
15 reductase or active fragments or variants thereof.

### BACKGROUND OF THE INVENTION

Biliverdin reductase (“BVR”) catalyzes reduction of the  $\gamma$ -meso bridge  
20 of biliverdin, an open tetrapyrrole, to produce bilirubin (Singleton et al., J. Biol. Chem. 240: 47890-4789 (1965); Tenhunen et al., Biochemistry 9:298-303 (1970);  
Colleran et al., Biochem J. 119:16P-19P (1970); Kutty et al., J. Biol. Chem.  
256:3956-3962 (1981); Buldain et al., Eur. J. Biochem. 156:179-184 (1986); Noguchi  
et al., Biochem J. 86:833-839 (1989)). In mammals, the oxidative cleavage of heme  
is catalyzed by the heme oxygenase system (Maines, Ann. Rev. Pharmacol. Toxicol.  
27:517-554 (1997)). Because open tetrapyrroles are generally believed to be devoid  
30 of biological functions, the enzymes that catalyze their formation have not  
traditionally been in the main stream of research activity. In plants, however,  
biliverdin analogues, phytochromobilins, function in photoregulatory capacity (Terry  
et al., J. Biol. Chem. 266:22215-22221 (1991); Cornejo et al., J. Biol. Chem.  
267:14790-14798 (1992)). Molecular cloning and biochemical analyses have shown  
35 that the enzyme, which in human is a 296 residue polypeptide, is highly conserved  
both at its primary structure and at its unique catalytic properties (Fakhrai et al., J.  
Biol. Chem. 267:4023-4029 (1992); McCoubrey et al., Eur. J Biochem. 222:597-603  
(1994); McCoubrey et al., Gene 160:235-240 (1995); Maines et al., Eur. J. Biochem.

235:372-381 (1996)). BVR is the only enzyme described to date with dual pH/dual adenine nucleotide cofactor requirements (Kutty et al., *J. Biol. Chem.* 256:3956-3962 (1981); Fakhrai et al., *J. Biol. Chem.* 267:4023-4029 (1992); Maines et al., *Eur. J. Biochem.* 235:372-381 (1996); Huang et al., *J. Biol. Chem.* 264:7844-7849 (1989)).

5 The reductase uses NADH in the acidic range (optimum range ~pH 6.0-6.7), whereas NADPH is utilized in the basic range (optimum range ~pH 8.5-8.7). BVR, which is a zinc metalloprotein (Maines et al., *Eur. J. Biochem.* 235:372-381 (1996)), possesses a HCX<sub>10</sub>CH or HCX<sub>10</sub>CC motif in the carboxy terminal third of the protein, which is similar to the zinc binding motif of protein kinase C (Hubbard et al., *Science* 10 254:1776-1779 (1991)) and may be the site of interaction of BVR with zinc.

BVR was previously thought to be simply a house-keeping enzyme found in most mammalian cells in excess of, or in disproportionate levels to, heme oxygenase isozymes (Ewing et al., *J. Neurochem.* 61:1015-1023 (1993)). Yet it has the above-noted noted unique and uncommon properties. Examination of the primary structure of human BVR, which recently became available (Maines et al., *Eur. J. Biochem.* 235:372-381 (1996)), revealed the presence of consensus sequences that are conserved in protein kinases, the most notable one being the GXGXXG motif near the N terminus of the protein that is found invariably in all kinases (Kamps et al., *Nature* 310:589-592 (1984); Hunter et al., *Ann. Rev. Biochem.* 54:897-930 (1985); Schlessinger, *Trend. Biochem. Sci.* 13:443-447 (1988); Hanks et al., *Science* 241:42-52 (1988); Yarden et al., *Annu. Rev. Biochem.* 57:443-478 (1988); Hanks et al., *Methods Enzymol.* 200:38-62 (1991)). A valine residue is present in BVR just 2 positions downstream from the last glycine of this motif. A valine residue is invariant at the corresponding position, as in BVR, in the family of kinases that phosphorylate 20 G-protein coupled receptors (Garcia-Bustos et al., *Biochim. Biophys. ACTA* 1071:83-101 (1991)). Database search results also identified additional similarities with PKGs, including a cluster of charged residues (KRNKR) in the carboxy terminus of BVR. Such clusters are a characteristic of the nuclear localization signal (“NLS”) (Garcia-Bustos et al., *Biochim. Biophys. ACTA* 1071:83-101 (1991)).

30 Although BVR has previously been identified as exhibiting protective effects against oxidative stress and as sharing characteristics with known kinases (see U.S. Patent Application Serial No. 09/606,129 to Maines, filed June 28, 2000), it is unclear the extent to which BVR is implicated in cellular repair mechanisms. The

present invention is directed to overcoming the above-identified deficiencies in the art.

## **SUMMARY OF THE INVENTION**

5

A first aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under conditions effective to modify the structure of the mammalian cell.

10

A second aspect of the present invention relates to a method of *in vivo* tissue remodeling in a mammal which includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein said delivering increases the intracellular concentration of biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.

15

A third aspect of the present invention relates to a method of repairing a damaged organ or organ system by performing the *in vivo* tissue modeling of the present invention, where the site of tissue remodeling is within the damaged organ or 20 organ system.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

25

Figures 1-6 show different images of HeLa cells transfected with human BVR DNA. Differences between untransfected cells (normal morphology) and transfected cells (immunostained) is readily apparent. The transfected cells show remarkable enlargement, altered cellular morphology including filopodia, and the appearance of spikes which are clearly observed.

30

## **DETAILED DESCRIPTION OF THE INVENTION**

35

The methods of modifying cell structure and remodeling tissue according to the present invention involve modulating the intracellular levels of biliverdin reductase (“BVR”) or active fragments thereof. Modulating intracellular levels of BVR can be achieved using known recombinant techniques directed to cells

or tissues to be affected, as described below, or by using known protein delivery techniques for delivering BVR into cells or tissues to be affected.

One form of human biliverdin reductase ("hBVR") has an amino acid sequence corresponding to SEQ. ID. No. 1 as follows:

5

	Met Asn Ala Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val			
1	5	10	15	
10	Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro			
	20	25	30	
	Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu			
	35	40	45	
15	Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser			
	50	55	60	
20	Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His			
	65	70	75	80
25	Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val			
	85	90	95	
30	Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu			
	100	105	110	
35	Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu			
	115	120	125	
40	Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp			
	130	135	140	
45	Leu Leu Lys Gly Ser Leu Leu Phe Thr Ser Asp Pro Leu Glu Glu Asp			
	145	150	155	160
50	Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu			
	165	170	175	
55	Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu			
	180	185	190	
60	Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu			
	195	200	205	
65	Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys			
	210	215	220	
70	Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn			
	225	230	235	240
75	Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn			
	245	250	255	
80	Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala			
	260	265	270	

Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile  
275 280 285  
5 Gln Lys Tyr Cys Cys Ser Arg Lys  
290 295

Heterologous expression and isolation of hBVR is described in Maines et al., Eur. J. Biochem. 235(1-2):372-381 (1996); Maines et al., Arch. Biochem. Biophys. 300(1):320-326 (1993), each of which is hereby incorporated by reference in its entirety. The DNA molecule encoding this form of hBVR has a nucleotide sequence corresponding to SEQ. ID. No. 2 as follows:

15	gggtggcgc ccggagctgc acggagagcg tgcccgtcag tgaccgaaga agagaccaag atgaatgcag agcccgagag gaagttggc gtgggtgtgg ttgggtgtgg ccgagccggc tccgtcgga tgagggactt gcggaatcca cacccttcct cagcgttcct gaacctgatt ggcttcgtgt cgagaaggga gctcgggagc attgatggag tccagcagat ttctttggag gatgctctt ccagccaaga ggtggaggc gcctatatct gcagtggagag ctccagccat	60 120 180 240 300
20	gaggactaca tcaggcagtt ccttaatgct ggcaagcacg tccttgtgga ataccccatg acactgtcat tggccggccgc tcaggaactg tggagctgg ctgagcagaa aggaaaagtc ttgcacgagg agcatgttga actcttgcgtg gaggaattcg ctttcctgaa aaaagaagtg gtggggaaag acctgctgaa agggtcgctc ctcttcacat ctgaccggcgtt ggaagaagac cggtttggct tccctgcatt cagcggcatc tctcgactga cctggctggt ctccctcttt	360 420 480 540 600
25	gggagcttt ctcttgcgtc tgccactttg gaagagcgaag aggaagatca gtatatgaaa atgacagtgt gtctggagac agagaagaaa agtccactgt catggattga agaaaaagga cctggtctaa aacgaaacag atatthaagc ttccatttca agtctgggtc cttggagaat gtgccaaatg taggagtgaa taagaacata tttctgaaag atcaaaaatat atttgtccag aaactcttgg gccagttctc tgagaaggaa ctggctgctg aaaagaaaacg catcctgcac	660 720 780 840 900
30	tgccctggggc ttgcagaaga aatccagaaa tattgctgtt caaggaagta agaggaggag gtgatgttagc acttccaaga tggcaccagc atttgggtct tctcaagagt tgaccattat ctctattctt aaaattaaac atgttgggaa aacaaaaaaaaaaaaaaa	960 1020 1070

The open reading frame which encodes hBVR of SEQ. ID. No. 1 extends from nt 1 to  
35 nt 888.

Another form of hBVR has an amino acid sequence according to SEQ. ID. No. 3 as follows:

Met Asn Thr Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val  
40 1 5 10 15

Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro  
20 25 30

5 Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu  
35 40 45

Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser  
50 55 60

10 Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His  
65 70 75 80

Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val  
15 85 90 95

Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu  
100 105 110

20 Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu  
115 120 125

Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp  
130 135 140

25 Leu Leu Lys Gly Ser Leu Leu Phe Thr Ala Gly Pro Leu Glu Glu  
145 150 155 160

Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu  
30 165 170 175

Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu  
180 185 190

35 Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu  
195 200 205

Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys  
210 215 220

40 Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn  
225 230 235 240

Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn  
45 245 250 255

Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala  
260 265 270

50 Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile  
275 280 285

Gln Lys Tyr Cys Cys Ser Arg Lys  
290 295

55

This hBVR sequence is reported at Komuro et al., NCBI Accession No. G02066,  
direct submission to the EMBL Data Library (1998), which is hereby incorporated by

reference in its entirety. Differences between the hBVR of SEQ. ID. No. 1 and the hBVR of SEQ. ID. No. 3 are at aa residues 3, 154, 155, and 160. Thus, residue 3 can be either alanine or threonine, residue 154 can be either alanine or serine, residue 155 can be either aspartic acid or glycine, and residue 160 can be either aspartic acid or 5 glutamic acid.

One form of rat biliverdin reductase ("rBVR") has an amino acid sequence corresponding to SEQ. ID. No. 4 as follows:

10	Met Asp Ala Glu Pro Lys Arg Lys Phe Gly Val Val Val Val Gly Val	1	5	10	15
	Gly Arg Ala Gly Ser Val Arg Leu Arg Asp Leu Lys Asp Pro Arg Ser		20	25	30
15	Ala Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu Gly	35	40	45	
	Ser Leu Asp Glu Val Arg Gln Ile Ser Leu Glu Asp Ala Leu Arg Ser	50	55	60	
20	Gln Glu Ile Asp Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His Glu	65	70	75	80
	Asp Tyr Ile Arg Gln Phe Leu Gln Ala Gly Lys His Val Leu Val Glu	85	90	95	
	Tyr Pro Met Thr Leu Ser Phe Ala Ala Gln Glu Leu Trp Glu Leu	100	105	110	
30	Ala Ala Gln Lys Gly Arg Val Leu His Glu Glu His Val Glu Leu Leu	115	120	125	
	Met Glu Glu Phe Glu Phe Leu Arg Arg Glu Val Leu Gly Lys Glu Leu	130	135	140	
35	Leu Lys Gly Ser Leu Arg Phe Thr Ala Ser Pro Leu Glu Glu Glu Arg	145	150	155	160
40	Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu Val	165	170	175	
	Ser Leu Phe Gly Glu Leu Ser Leu Ile Ser Ala Thr Leu Glu Glu Arg	180	185	190	
45	Lys Glu Asp Gln Tyr Met Lys Met Thr Val Gln Leu Glu Thr Gln Asn	195	200	205	
	Lys Gly Leu Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys Arg	210	215	220	
50	Asn Arg Tyr Val Asn Phe Gln Phe Thr Ser Gly Ser Leu Glu Glu Val	225	230	235	240

Pro Ser Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asp Ile  
245 250 255

5 Phe Val Gln Lys Leu Leu Asp Gln Val Ser Ala Glu Asp Leu Ala Ala  
260 265 270

Glu Lys Lys Arg Ile Met His Cys Leu Gly Leu Ala Ser Asp Ile Gln  
275 280 285

10 Lys Leu Cys His Gln Lys Lys  
290 295

Heterologous expression and isolation of rBVR is described in Fakhrai et al., *J. Biol. Chem.* 267(6):4023-4029 (1992), which is hereby incorporated by reference in its entirety. The rBVR of SEQ. ID. No. 4 shares about 82% aa identity to the hBVR of SEQ. ID. No. 1, with variations in aa residues being highly conserved. The DNA molecule encoding this form of rBVR has a nucleotide sequence corresponding to SEQ. ID. No. 5 as follows:

20 ggtcaacagc taagtgaagc catatccata gagagttgt gccagtgcgg caagatcctg 60  
aacctctgtc tgtcttcgga cactgactga agagaccgag atggatgcgg agccaaagag 120  
gaaatttggaa gtggtagtgg ttgggtttgg cagagctggc tcggtgaggc tgagggactt 180  
gaaggatcca cgctctgcag cattcctgaa cctgatttggaa tttgtgtcca gacgagagct 240

25 tggagcctt gatgaagtac ggcagatttc tttggaaagat gctctccgaa gccaagagat 300  
tgatgtcgcc tatatttgca gtgagagttc cagccatgaa gactatatac ggcagttct 360  
gcaggctggc aagcatgtcc tcgttggaaata ccccatgaca ctgtcatttgc cggcggccca 420  
ggagctgtgg gagctggccg cacagaaagg gagagtcctg catgaggagc acgtggaaact 480  
cttgcattggag gaattcgaat tccttggaaag agaagtgttg gggaaagagc tactgaaagg 540

30 gtctcttcgc ttcacagcta gcccacttggaa agaagagaga tttggcttcc ctgcgttcag 600  
cggcatttct cgcctgaccc ggctggtctc cctcttcggg gagctttctc ttatattctgc 660  
caccttggaa gagcgaaaag aggatcagta tatgaaaatg accgtgcagc tggagaccca 720  
gaacaagggt ctgctgtcat ggatttggaa gaaaggccct ggctaaaaaa gaaacagata 780  
tgtaaaacttc cagttcactt ctgggtccct ggaggaagtgg ccaagtgttag gggtcaataa 840

35 gaacattttc ctgaaagatc aggatataatt tgttcagaag ctcttagacc aggtctctgc 900  
agaggacctg gctgctgaga agaagcgtcat catgcattgc ctggggctgg ccagcgcacat 960  
ccagaagctt tgccaccaga agaagtgaag aggaagcttc agagacttct gaagggggcc 1020  
agggtttgggt cctatcaacc attcaccttt agctcttaca attaaacatg tcagataaac 1080  
a 1081

40 The open reading frame which encodes rBVR of SEQ. ID. No. 4 extends from nt 1 to nt 885.

By way of example, hBVR of SEQ. ID. No. 1 is characterized by a number of functional domains, including putative and/or demonstrated phosphorylation sites from aa 15 to 20, aa 21 to 23, aa 44 to 46 or 47, aa 49 to 54, aa 58 to 61, aa 64 to 67, aa 78 to 81, aa 79 to 82, aa 189 to 192, aa 207 to 209, aa 214 to 217, aa 222 to 227, aa 236 to 241, aa 245 to 250, aa 267 to 269 or 270, and aa 294 to 296; a basic N-terminal domain characterized by aa 6 to 8; a hydrophobic domain characterized by aa 9 to 14 (FXVVVV, SEQ. ID. No. 6); a nucleotide binding domain characterized by aa 15 to 20 (GXGXXG, SEQ. ID. No. 7); an oxidoreductase domain characterized by aa 90 to 97 (AGLHVLVE, SEQ. ID. No. 8); a leucine zipper spanning aa 129 to 157 (LX<sub>6</sub>LX<sub>6</sub>KX<sub>6</sub>LX<sub>6</sub>L, SEQ. ID. No. 9); several kinase motifs, including aa 44 to 46 (SRR, SEQ. ID. No. 10), aa 147 to 149 (KGS, SEQ. ID. No. 11) and aa 162 to 164 (FTX, SEQ. ID. No. 12); a nuclear localization signal spanning aa 222 to 228 (GLKRNRY, SEQ. ID. No. 13); a myristylation site spanning aa 221 to 225 (PGLKR, SEQ. ID. No. 14); a zinc finger domain spanning aa 280 to 293 (HCX<sub>10</sub>CC, SEQ. ID. No. 15); and substrate binding domains including, without limitation, a protein kinase C (“PKC”) enhancing domain spanning aa 275 to 281 (KKRIXHC, SEQ. ID. No. 16) and a PKC inhibiting domain spanning aa 290 to 296 (QKXCXXXX, SEQ. ID. No. 17). By way of sequence comparison and, in consideration of conserved substitutions, hBVR of SEQ. ID. No. 3 and rBVR of SEQ. ID. No. 4 include similar functional domains. For example rBVR includes an identical hydrophobic domain, an identical nucleotide binding domain, an identical oxidoreductase domain, a conserved leucine zipper domain (with residue variations between L and K residues), identical or conserved kinase motifs, an identical nuclear localization signal, an identical myristylation site, a conserved zinc finger domain (with terminal C residue replaced by H), a conserved PKC enhancing domain, and a conserved PKC inhibiting domain.

DNA molecules encoding a BVR protein or polypeptide can also include a DNA molecule that hybridizes under stringent conditions to the DNA molecule having a nucleotide sequence of SEQ. ID. No. 2 or SEQ. ID. No. 5. An example of suitable stringency conditions is when hybridization is carried out at a temperature of about 37°C using a hybridization medium that includes 0.9M sodium citrate (“SSC”) buffer, followed by washing with 0.2x SSC buffer at 37°C. Higher stringency can readily be attained by increasing the temperature for either

100-45545-00000

hybridization or washing conditions or increasing the sodium concentration of the hybridization or wash medium. Nonspecific binding may also be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to 5 the hybridization buffer, and treatment with RNase. Wash conditions are typically performed at or below stringency. Exemplary high stringency conditions include carrying out hybridization at a temperature of about 42°C to about 65°C for up to about 20 hours in a hybridization medium containing 1M NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 0.2% ficoll, 0.2% 10 polyvinylpyrrolidone, 0.2% bovine serum albumin, and 50 µg/ml *E. coli* DNA, followed by washing carried out at between about 42°C to about 65°C in a 0.2x SSC buffer.

The BVR protein or polypeptide can also be a fragment of the above biliverdin reductase proteins or polypeptides or a variant thereof.

15                   Fragments of BVR preferably contain one or more of the above-listed functional domains, and possess one or more of the activities of full length BVR. Suitable fragments can be produced by several means. Subclones of a gene encoding a known BVR can be produced using conventional molecular genetic manipulation for subcloning gene fragments, such as described by Sambrook et al., Molecular 20 Cloning: A Laboratory Manual, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), and Ausubel et al. (ed.), Current Protocols in Molecular Biology, John Wiley & Sons (New York, NY) (1999 and preceding editions), each of which is hereby incorporated by reference in its entirety. The subclones then are expressed *in vitro* or *in vivo* in bacterial cells to yield a smaller protein or polypeptide that can be 25 tested for a particular activity, e.g., converting biliverdin to bilirubin, modifying cell structure, etc., as discussed *infra*. See also Huang et al., J. Biol. Chem. 264:7844-7849 (1989), which is hereby incorporated by reference in its entirety.

In another approach, based on knowledge of the primary structure of the protein, fragments of a BVR gene may be synthesized using the PCR technique 30 together with specific sets of primers chosen to represent particular portions of the protein. Erlich et al., Science 252:1643-51 (1991), which is hereby incorporated by reference in its entirety. These can then be cloned into an appropriate vector for expression of a truncated protein or polypeptide from bacterial cells as described

above. For example, oligomers of at least about 15 to 20 nt in length can be selected from the nucleic acid molecules of SEQ. ID. No. 2 and SEQ ID. No. 5 for use as primers.

In addition, chemical synthesis can also be employed using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, J. Am. Chem. Assoc. 85:2149-2154 (1964), which is hereby incorporated by reference in its entirety) or synthesis in homogenous solution (Houbenweyl, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15, I and II, Thieme, Stuttgart (1987), which is hereby incorporated by reference in its entirety).

10 Variants of suitable BVR proteins or polypeptides can also be expressed. Variants may be made by, for example, the deletion, addition, or alteration of amino acids that have either (i) minimal influence on certain properties, secondary structure, and hydrophobic nature of the polypeptide or (ii) substantial effect on one or more properties of BVR. Variants of BVR can also be fragments of BVR which 15 include one or more deletion, addition, or alteration of amino acids of the type described above. The BVR variant preferably contains a deletion, addition, or alteration of amino acids within one of the above-listed functional domains. The substituted or additional amino acids can be either L-amino acids, D-amino acids, or modified amino acids, preferably L-amino acids. Whether a substitution, addition, or deletion results in modification of BVR variant activity may depend, at least in part, 20 on whether the altered amino acid is conserved. Conserved amino acids can be grouped either by molecular weight or charge and/or polarity of R groups, acidity, basicity, and presence of phenyl groups, as is known in the art.

25 A number of BVR variants have been described in co-pending U.S. Patent Application Serial No. 09/606,129 to Maines, filed June 28, 2000, which is hereby incorporated by reference in its entirety.

Variants may also include, for example, a polypeptide conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, identification, or therapeutic use (i.e., delivery) of the polypeptide.

The BVR protein or polypeptide can be recombinantly produced, isolated, and then purified, if necessary. When recombinantly produced, the

biliverdin reductase protein or polypeptide is expressed in a recombinant host cell, typically, although not exclusively, a prokaryote.

When a prokaryotic host cell is selected for subsequent transformation, the promoter region used to construct the recombinant DNA molecule (i.e., transgene) should be appropriate for the particular host. The DNA sequences of eukaryotic promoters, as described *infra* for expression in eukaryotic host cells, differ from those of prokaryotic promoters. Eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system, and, further, prokaryotic promoters are not recognized and do not function in eukaryotic cells.

Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. Efficient translation of mRNA in prokaryotes requires a ribosome binding site called the Shine-Dalgarno ("SD") sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3'-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, Methods in Enzymology, 68:473 (1979), which is hereby incorporated by reference in its entirety.

Promoters vary in their "strength" (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in *E. coli*, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, *lac* promoter, *trp* promoter, *recA* promoter, ribosomal RNA promoter, the *P<sub>R</sub>* and *P<sub>L</sub>* promoters of coliphage lambda and others, including but not limited, to *lacUV5*, *ompF*, *bla*, *lpp*, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid *trp-lacUV5* (*tac*) promoter or other *E. coli* promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.

Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operons, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the *lac* operon is induced by the addition of lactose or IPTG 5 (isopropylthio-beta-D-galactoside). A variety of other operons, such as *trp*, *pro*, etc., are under different controls.

Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantity of gene specific 10 messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in *E. coli* requires a Shine-Dalgarno ("SD") sequence about 7-9 bases 5' to the initiation codon ("ATG") to provide a ribosome binding site. Thus, any SD-ATG combination 15 that can be utilized by host cell ribosomes may be employed. Such combinations include, but are not limited to, the SD-ATG combination from the *cro* gene or the *N* gene of coliphage lambda, or from the *E. coli* tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other 20 techniques involving incorporation of synthetic nucleotides may be used.

Mammalian cells can also be used to recombinantly produce BVR or fragments or variants thereof.

Suitable mammalian host cells include, without limitation: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573), CHOP, and NS-1 25 cells. Suitable expression vectors for directing expression in mammalian cells generally include a promoter, as well as other transcription and translation control sequences known in the art. Common promoters include, without limitation, SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.

30 Regardless of the selection of host cell, once the DNA molecule coding for a biliverdin reductase protein or polypeptide, or fragment or variant thereof, has been ligated to its appropriate regulatory regions using well known molecular cloning techniques, it can then be introduced into a suitable vector or otherwise introduced

directly into a host cell using transformation protocols well known in the art (Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety).

5           The recombinant molecule can be introduced into host cells via transformation, particularly transduction, conjugation, mobilization, or electroporation. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like. The host cells, when grown in an appropriate medium, are capable of expressing the biliverdin reductase, or fragment or variant thereof, which can then be isolated therefrom and, if necessary, purified.

10           The BVR, or fragment or variant thereof, is preferably produced in purified form (preferably at least about 60%, more preferably 80%, pure) by conventional techniques.

15           For therapeutic purposes, the treated cell is preferably *in vivo* and the protein or polypeptide or RNA molecule is delivered into the cell in a manner which affords the protein or polypeptide or RNA molecule to be active within the cell. A number of known delivery techniques can be utilized for the delivery, into cells, of either proteins or polypeptides or RNA, or DNA molecules encoding them.

20           Regardless of the particular method of the present invention which is practiced, when it is desirable to contact a cell (i.e., to be treated) with a protein or polypeptide or RNA molecule, it is preferred that the contacting be carried out by delivery of the protein or polypeptide or RNA molecule into the cell.

25           One approach for delivering protein or polypeptides or RNA molecules into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that protein or polypeptide or RNA to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the protein or polypeptide or RNA into the cell.

30           Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the

encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the 5 half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.

In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the 10 environment becomes acidic near the liposome membrane (see, e.g., Proc. Natl. Acad. Sci. USA 84:7851 (1987); Biochemistry 28:908 (1989), which is hereby incorporated by reference in its entirety). When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.

15 Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve "on demand" drug delivery. The same problem exists for pH-20 sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.

25 This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.

Different types of liposomes can be prepared according to Bangham et al., J. Mol. Biol. 13:238-252 (1965); U.S. Patent No. 5,653,996 to Hsu et al.; U.S. Patent No. 5,643,599 to Lee et al.; U.S. Patent No. 5,885,613 to Holland et al.; U.S. Patent No. 5,631,237 to Dzau et al.; and U.S. Patent No. 5,059,421 to Loughrey et al., 30 each of which is hereby incorporated by reference in its entirety.

An alternative approach for delivery of proteins or polypeptides involves the conjugation of the desired protein or polypeptide to a polymer that is stabilized to avoid enzymatic degradation of the conjugated protein or polypeptide.

Conjugated proteins or polypeptides of this type are described in U.S. Patent No. 5,681,811 to Ekwuribe, which is hereby incorporated by reference in its entirety.

Yet another approach for delivery of proteins or polypeptides involves preparation of chimeric proteins according to U.S. Patent No. 5,817,789 to Heartlein et al., which is hereby incorporated by reference in its entirety. The chimeric protein can include a ligand domain and, e.g., BVR or a fragment or variant thereof. The ligand domain is specific for receptors located on a target cell. Thus, when the chimeric protein is delivered intravenously or otherwise introduced into blood or lymph, the chimeric protein will adsorb to the targeted cell, and the targeted cell will internalize the chimeric protein.

When it is desirable to achieve heterologous expression of a desirable protein or polypeptide or RNA molecule in a target cell, DNA molecules encoding the desired protein or polypeptide or RNA can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the protein or polypeptide and then introducing the nucleic acid molecule into the cell under conditions effective to express the protein or polypeptide or RNA in the cell. Preferably, this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.

When transforming mammalian cells for heterologous expression of a protein or polypeptide, an adenovirus vector can be employed. Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner, Biotechniques 6:616-627 (1988) and Rosenfeld et al., Science 252:431-434 (1991), WO 93/07283, WO 93/06223, and WO 93/07282, each of which is hereby incorporated by reference in its entirety. Adeno-associated viral gene delivery vehicles can be constructed and used to deliver a gene to cells. The use of adeno-associated viral gene delivery vehicles *in vitro* is described in Chatterjee et al., Science 258:1485-1488 (1992); Walsh et al., Proc. Nat'l. Acad. Sci. 89:7257-7261 (1992); Walsh et al., J. Clin. Invest. 94:1440-1448 (1994); Flotte et al., J. Biol. Chem. 268:3781-3790 (1993); Ponnazhagan et al., J. Exp. Med. 179:733-738 (1994); Miller et al., Proc. Nat'l Acad. Sci. 91:10183-10187 (1994); Einerhand et al., Gene Ther. 2:336-343 (1995); Luo et al., Exp. Hematol. 23:1261-1267 (1995); and Zhou et al., Gene Ther. 3:223-229 (1996), each of which is hereby incorporated by reference in its entirety. *In vivo* use of these vehicles is described in Flotte et al., Proc. Nat'l Acad.

RECEIVED  
U.S. PATENT AND  
TRADEMARK  
OFFICE  
APR 20 1998

Sci. 90:10613-10617 (1993); and Kaplitt et al., Nature Genet. 8:148-153 (1994), each of which is hereby incorporated by reference in its entirety. Additional types of adenovirus vectors are described in U.S. Patent No. 6,057,155 to Wickham et al.; U.S. Patent No. 6,033,908 to Bout et al.; U.S. Patent No. 6,001,557 to Wilson et al.; U.S. Patent No. 5,994,132 to Chamberlain et al.; U.S. Patent No. 5,981,225 to Kochanek et al.; and U.S. Patent No. 5,885,808 to Spooner et al.; and U.S. Patent No. 5,871,727 to Curiel, each of which is hereby incorporated by reference in its entirety.

Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired protein or polypeptide or RNA product into a target cell. One such type of retroviral vector is disclosed in U.S. Patent No. 5,849,586 to Kriegler et al., which is hereby incorporated by reference in its entirety.

Regardless of the type of infective transformation system employed, it can be targeted for delivery of the nucleic acid to a specific cell type. For example, 15 for delivery of the nucleic acid into specific cells, a high titer of the infective transformation system can be injected directly within the desired site so as to enhance the likelihood of cell infection within the desired site. The infected cells will then express the desired protein product, in this case BVR, or fragments or variants thereof, to modify the structure of those cells which have been infected.

20                    Whether the proteins or polypeptides or nucleic acids are administered alone or in combination with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, or in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions, they can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitory or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes. For most therapeutic purposes, the proteins or polypeptides or nucleic acids can be administered intravenously.

For injectable dosages, solutions or suspensions of these materials can be prepared in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of

petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.

5 For use as aerosols, the proteins or polypeptides or nucleic acids in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.

10 Both the biliverdin reductase and fragments or variants thereof can be delivered to the target cells (i.e., at or around the site where cell modification is desired) using the above-described methods for delivering such therapeutic products. In delivering the therapeutic products to nerve cells in the brain, consideration should be provided to negotiation of the blood-brain barrier. The blood-brain barrier

15 typically prevents many compounds in the blood stream from entering the tissues and fluids of the brain. Nature provides this mechanism to insure a toxin-free environment for neurologic function. However, it also prevents delivery to the brain of compounds, in this case neuroprotective compounds that can inhibit nerve cell death following an ischemic event.

20 One approach for negotiating the blood-brain barrier is described in U.S. Patent No. 5,752,515 to Jolesz et al., which is hereby incorporated by reference in its entirety. Basically, the blood-brain barrier is temporarily "opened" by targeting a selected location in the brain and applying ultrasound to induce, in the central nervous system (CNS) tissues and/or fluids at that location, a change detectable by

25 imaging. A protein or polypeptide or RNA molecule of the present invention can be delivered to the targeted region of the brain while the blood-brain barrier remains "open," allowing targeted neuronal cells to uptake the delivered protein or polypeptide or RNA. At least a portion of the brain in the vicinity of the selected location can be imaged, e.g., via magnetic resonance imaging, to confirm the location

30 of the change. Alternative approaches for negotiating the blood-brain barrier include chimeric peptides and modified liposome structures which contain a PEG moiety (reviewed in Pardridge, *J. Neurochem.* 70:1781-1792 (1998), which is hereby incorporated by reference in its entirety), as well as osmotic opening (i.e., with

PROPRIETARY MATERIAL  
© 2001

bradykinin, mannitol, RPM7, etc.) and direct intracerebral infusion (Kroll et al., *Neurosurgery* 42(5):1083-1100 (1998), which is hereby incorporated by reference in its entirety).

Analysis of the promoter region associated with the nucleic acid  
5 encoding rBVR indicates the presence of recognition sites for several regulating  
proteins, including INF-1, an enhancer of cytokine and virus-induced transcriptional  
activation, and AP-1, the proto-oncogene binding site (McCoubrey et al., "The  
Structure, Organization and Differential Expression of the Rat Gene Encoding  
Biliverdin Reductase," Gene 160:235-240 (1995), which is hereby incorporated by  
10 reference in its entirety. Also, two elements known to be involved in embryonic gene  
expression, P3A and engrailed, are present in the promoter region of this gene. These  
criteria are consistent with the function of BVR in a regulatory capacity in the cell.

As discussed in greater detail in the Examples, it has been discovered that transformation of mammalian cells with biliverdin reductase is effective in 15 modifying the structure of the transformed mammalian cells. It is believed that the increase in biliverdin reductase in the cell is responsible for having modified cell structure. Therefore, one aspect of the present invention relates to a method of modifying cell structure which includes: increasing the intracellular concentration of biliverdin reductase, or a fragment or variant thereof, in a mammalian cell under 20 conditions effective to modify the structure of the mammalian cell.

Where the cellular concentration of biliverdin reductase is increased, it should be appreciated that some basal level of biliverdin reductase may exist in the cell which has been targeted. Thus, the increase in biliverdin reductase intracellular concentration is simply the result of causing more biliverdin reductase to be expressed (e.g., inducing or transforming) or introducing additional biliverdin reductase from an external source (i.e., administration).

In contrast, because biliverdin reductase fragments and variants are not normally expressed in mammalian cells, any increase in biliverdin reductase fragments or variants is the result of their heterologous expression (i.e., transforming or introducing biliverdin reductase fragments or variants from an external source (i.e., administering).

Regardless of whether it is biliverdin reductase or its fragments or variants whose cellular concentration is increased in the mammalian cell to be

modified, the increase in concentration can be achieved by introducing the BVR or BVR fragments or variants into the cell. Typically, this is done by contacting the mammalian cell (to be modified) with a delivery vehicle which includes biliverdin reductase or a fragment or variant thereof. The delivery vehicle can be any delivery vehicle of the type described above for protein delivery.

Likewise, such increase in cellular concentration can be achieved by heterologous expression by the mammalian cell (to be modified). Such heterologous expression is typically the result of transforming the mammalian cell with a nucleic acid encoding biliverdin reductase or a fragment or variant thereof under conditions effective for expression of the biliverdin reductase or the fragment or variant thereof in the mammalian cell. The transformation can be achieved using any nucleic acid delivery system of the type described above. (e.g., infective transformation).

The mammalian cells which can be treated include, without limitation, stem cells (both omnipotent and pluripotent stem cells), neuronal or glial cells, vascular smooth muscle cells, skeletal muscle cells, epithelial cells, and nucleated blood cells (e.g., macrophages and other blood cells). The mammalian cells whose structure is modified can be either *in vitro* or *in vivo* when their structure is modified.

Exemplary aspects of the mammalian cell structure which can be modified in accordance with the present invention include, without limitation, enhanced cell size (i.e., forming giant cells), actin microspike formation, polar cell morphology (i.e., with protracted filopodia extensions), and a combination thereof.

Without being bound by theory, it is believed that the modified cell structure is the result of biliverdin reductase interaction with proteins and kinases that govern cell cycling and with polypeptide growth factors.

In view of the modified cell structure, it is further contemplated that the present invention can be utilized to perform organogenesis, tissue remodeling, wound healing, angiogenesis, or combinations thereof. Tissue remodeling, of course, encompasses both wound healing and angiogenesis.

Thus, a further aspect of the present invention relates to a method of performing *in vivo* tissue remodeling in a mammal. This aspect of the invention includes: delivering biliverdin reductase, or fragments or variants thereof, to one or more cells present at a site of tissue remodeling in a mammal, wherein the delivering (of BVR or its fragments or variants) increases the intracellular concentration of

10045545.01402

biliverdin reductase, or fragments or variants thereof, under conditions effective to modify the structure of the one or more cells at the site of tissue remodeling, thereby remodeling the tissue containing the one or more cells.

Tissues which can be remodeled *in vivo* include, without limitation,

5      epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissue. More specifically, angiogenesis can implicate remodeling of vascular tissue and modifying the structure of vascular smooth muscle, bladder, and urinary tract cells. Likewise, wound healing can implicate remodeling of epithelial tissues, nerve tissues, muscular tissues (both smooth muscle and skeletal muscle tissues), or connective tissues via modifying the structures of epithelial cells,

10     nerve or glial cells, vascular and skeletal muscle cells, etc.

As a result of such tissue remodeling, where multiple tissues are remodeled, it also contemplated to utilize the present invention according to a method of repairing a damaged organ or organ system by performing the method of *in vivo* tissue remodeling in accordance with the present invention, where the site of tissue remodeling is within the damaged organ or organ system. Exemplary organ or organ systems which can be subject to repair include, without limitation, skin, liver, nervous system (e.g., both sensory neurons and motor neurons), cardiovascular system, and urogenital tract.

20       With respect specifically to wound healing, it should be appreciated that the primary goal in the treatment of wounds is to achieve wound closure. Open cutaneous wounds represent one major category of wounds and include burn wounds, neuropathic ulcers, pressure sores, venous stasis ulcers, and diabetic ulcers. Open cutaneous wounds routinely heal by a process which comprises six major components: i) inflammation, ii) fibroblast proliferation, iii) blood vessel proliferation, iv) connective tissue synthesis v) epithelialization, and vi) wound contraction. Wound healing is impaired when these components, either individually or as a whole, do not function properly. Numerous factors can affect wound healing, including malnutrition, infection, pharmacological agents (e.g., actinomycin and steroids), diabetes, and advanced age (see Hunt and Goodson, 1988). In general, agents which promote a more rapid influx of fibroblasts, endothelial and epithelial cells into wounds should increase the rate at which wounds heal. By virtue of increasing the intracellular concentration of biliverdin reductase, it becomes possible

to induce an increase in cell size, the formation of actin microspikes, and morphological changes in cell polarity, i.e., formation of filopodia extensions. These aspects suggest that the affected cells can be made more readily able to influx into damage sites in need of repair.

5           The use of BVR for wound healing can also be carried out in combination with a medicament selected from the group consisting of an antibacterial agent, an antiviral agent, an antifungal agent, an antiparasitic agent, an anti-inflammatory agent, an analgesic agent, an antipruritic agent, or a combination thereof. For cutaneous wound healing, a preferred mode of administration is by the  
10           topical route.

## EXAMPLES

15           The following examples are intended to illustrate, but by no means are intended to limit, the scope of the present invention as set forth in the appended claims.

**Example 1 - *In Vitro* Transformation of HeLa Cells with Biliverdin Reductase for Modifying Cellular Structure**

20           HeLa cells were transfected *in vitro* with biliverdin reductase encoding DNA. A HeLa cell suspension having a density of about  $12 \times 10^4$ /ml was introduced to a 12-well plate using 0.2 ml of the cell suspension per well (i.e., about  $2.4 \times 10^4$  cells per well). The following protocol was employed for transfection:

25           Cells were washed with DMEM(serum). Thereafter, the following solution was added: 2  $\mu$ l of DNA ( 541 0.5  $\mu$ g/ $\mu$ l), 50  $\mu$ l of DMEM(-), and 2  $\mu$ l of lipofectimine. After 4-5 h, 0.5 ml of DMEM (20% serum) was added followed by 30 h incubation (37°C).

30           On the following day cells were immunostained using the following protocol. HeLa cells were washed once for 5 min in PBS (0.1% PB, 0.9% NaCl), followed by treatment with 4% PFA (on ice). 10 min later, cells were washed 3 times for 5 min each time in PBS. Cells were blocked by treatment with PBS (950  $\mu$ l) + 50  $\mu$ l horse serum (5% HS PBS) for 1 h at room temperature. Cells were treated with a

solution of 3% HS – 0.25% Triton-PBS at 4°C overnight, thereafter cells were treated with 1:1000 dilution of BVR antibody.

For antibody staining, cells were washed 3 times for 5 min each time in PBS – 0.25% Triton x 100 and treated with second antibody solution consisting of :

5 horse serum, 15  $\mu$ l/ml and antimouse-IgG, 5 $\mu$ l/ml. After 3 times washing with PBS  
for 5 min each time, cells were visualized using ABC solution (Vector Labs) and  
stained for 30 min.

Non specific staining was removed using 3% of H<sub>2</sub>O<sub>2</sub>. Cells were then washed with dd H<sub>2</sub>O and dehydrated in 95%-100% ethanol, xylene 5 min. Slides were mounted with 1/2 permount + 1/2 xylene

10 were mounted with  $\frac{1}{2}$  permount +  $\frac{1}{2}$  xylene

Control and transformed HeLa cells were visualized by immunostaining using antibody to BVR. As shown in Figures 1-6, the transformed HeLa cells displayed larger cell size relative to control cells, formation of actin microspikes, and polar cell morphology with filopodia extensions.

15 The above results indicate that BVR is a regulator of cell proliferation and cell differentiation. Following transformation to induce an increase in BVR expression, transfected cells were transformed into giant cells several times the size of normal cells. Moreover, the transfected cells displayed formation of actin microspikes. Such actin microspikes are known to act as sensory devices by which 20 cells explore their environment. Also, BVR transfected cells exhibited polar cell morphology, as characterized by protracted filopodia extensions that resemble that of neuronal axon and dendritic extensions, a phenotype which is not displayed by Cdc42 transfected cells (Adams and Schwarz, "Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42," *J. Cell Biol.* 150:807- 25 822 (2000), which is hereby incorporated by reference in its entirety). These properties are displayed by certain cyclin-dependent kinases. Specifically, Cdc42 kinase stimulates spike formation (Kozma et al., "The Ras-related protein Cdc42Hs and Bradykinin Promote Formation of Peripheral Actin Microspikes and Filopodia in Swiss 3T3 Fibroblasts," *Mol. Cell Biol.* 15:1942-1952 (1995); Nobes and Hall, "Rho, 30 Rac, and Cdc42 GTPases Regulate the Assembly of Multimolecular Focal Complexes Associated with Actin Stress Fibers, Lamellipodia, and Filopodia," *Cell* 81:53-62 (1995); Adams and Schwarz, "Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42," *J. Cell Biol.* 150:807-822 (2000), each of

which is hereby incorporated by reference in its entirety) and D type cyclins, e.g., cyclin D<sub>2</sub>, deregulate cell size and cause cell mass increase (Kershoff and Ziff, "Cyclin D<sub>2</sub> Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum," EMBO J. 14:1892-1903 (1995), which is hereby incorporated by reference in its entirety). These proteins require cooperation of signal transduction kinase activity, e.g., GTPases Rac/Ha-Ras (Adams and Schwarz, "Stimulation of Fasein Spikes by Thrombospondin-1 is Mediated by GTPases Rac and Cdc42," J. Cell Biol. 150:807-822 (2000); Kershoff and Ziff, "Cyclin D<sub>2</sub> and Ha-Ras Transformed Rat Embryo Fibroblasts Exhibit Novel Deregulation of Cell Size Control and Early S Phase Arrest in Low Serum," EMBO J. 14:1892-1903 (1995), each of which is hereby incorporated by reference in its entirety). BVR, as noted above, is a protein kinase and has both cell proliferating and cell differentiation activities. Furthermore, BVR can unexpectedly control the cell size under normal conditions, whereas cyclin D<sub>2</sub> and Ha-Ras transformed cells only display giant size in low serum conditions. The morphology of the above-described transformed cells is also consistent with the use of BVR expression for promoting axonal growth in the case of nerve damage.

In a number of amino acid sequences, X is used to depict a residue which can be any naturally occurring amino acid, unless otherwise indicated.

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.